Results 171 to 180 of about 8,835 (210)

Results of radiotherapy for thyroid ophthalmopathy

International Journal of Radiation Oncology*Biology*Physics, 1989
Between October, 1978 and August, 1986, 35 patients with thyroid ophthalmopathy were treated with radiotherapy. Twenty-eight patients had treatment with corticosteroids prior to radiotherapy and either progressed on steroids or relapsed during tapering. Seven patients with contraindications to steroids were treated primarily with radiotherapy.
H M, Sandler, J H, Rubenstein, B L, Fowble, R C, Sergott, P J, Savino, T M, Bosley   +5 more
openaire   +2 more sources

The pathogenesis of thyroid-associated ophthalmopathy

Journal of Endocrinology, 1989
TAO is an autoimmune disease the pathogenesis of which is unclear. Autoimmunity against orbital antigens has been demonstrated, although the precise immunological mechanisms responsible are unidentified. Cytokines probably play an important mediating role.
P, Perros, P, Kendall-Taylor
openaire   +2 more sources

Management of thyroid ophthalmopathy

Current Opinion in Ophthalmology, 1996
The pathogenesis of thyroid ophthalmopathy and its relation to thyroid gland dysfunction defies elucidation, and thus only palliative therapy exists. If and how antithyroid therapy affects the course of thyroid eye disease remains controversial. Research continues to try to reveal a subset of patients who respond best to corticosteroid or radiation ...
openaire   +2 more sources

Pathogenesis of thyroid-associated ophthalmopathy

Trends in Endocrinology & Metabolism, 1993
Thyroid-associated ophthalmopathy is a complex disease whose pathogenesis is thought to be autoimmune. Evidence has accumulated to implicate lymphocytes, antibodies, and cytokines targeting the orbital tissues whose structural and functional characteristics are unique.
P, Perros, P, Kendall-Taylor
openaire   +2 more sources

The pathophysiology of thyroid-associated ophthalmopathy

Ophthalmology Clinics of North America, 2002
TAO is an inflammatory disease of the orbital tissues. The effects of inflammation, mediated through cytokine release, include proliferation of fibroblasts, increased deposition of extracellular matrix, and adipocyte differentiation and proliferation. As a result, edema, enlargement of the extraocular muscles, and increased volume of the orbital soft ...
Mark P, Hatton, Peter A D, Rubin
openaire   +2 more sources

Thyroid ophthalmopathy.

Minerva endocrinologica, 2006
Thyroid associated ophthalmopathy (TAO) is an inflammatory orbital disease of autoimmune origin with the potential to cause severe functional and psychosocial effects. It presents one of the most difficult challenges in the clinical practice of ophthalmology. Pathogenesis of the disease is not yet fully understood. It is usually associated with thyroid
J, Levy, R, Sobel, M, Marcus, T, Lifshitz   +3 more
openaire   +1 more source

Octreoscan in Thyroid-Associated Ophthalmopathy

Thyroid, 2002
Until recently, there was no imaging technique available that could be considered as a reliable measure of inflammation in thyroid-associated opthalmopathy (TAO). Pentetreotide (a synthetic derivative of somatostatin) labeled with 111In has been used to visualize somatostatin receptors in endocrine-related tumours in vivo.
openaire   +2 more sources

Treating the thyroid in the presence of Graves’ ophthalmopathy

Best Practice & Research Clinical Endocrinology & Metabolism, 2012
The etiology of Graves' orbitopathy (GO) remains enigmatic. Optimal therapeutic choices for the hyperthyroidism associated with Graves' disease (GD) in the presence of GO remain controversial. Whether antithyroid drugs (ATDs), radioiodine (RAI), or thyroidectomy should be favored in such patients remains debated. Pre-therapy variables such as ethnicity,
Hegedüs, Laszlo, Bonnema, Steen J, Smith, Terry J, Brix, Thomas H   +3 more
openaire   +2 more sources

Azathioprine in the treatment of thyroid-associated ophthalmopathy

Acta Endocrinologica, 1990
Abstract Azathioprine is used in the treatment of thyroid-associated ophthalmopathy, but its effectiveness has not been evaluated. In the present study 20 patients with moderately severe ophthalmopathy were recruited; 10 patients received azathioprine and the other 10 matched patients served as controls. During the treatment period (lasting 1 year) and
P, Perros, D R, Weightman, A L, Crombie, P, Kendall-Taylor   +3 more
openaire   +2 more sources

Thyroid-Associated Ophthalmopathy

2011
Eye symptoms are a common feature of Graves’ disease, where the symptoms have an underlying immunological cause. Several designations have been used: endocrine ophthalmopathy, dysthyroid orbitopathy, dysthyroid ophthalmopathy, orbitopathy, infiltrative ophthalmopathy and thyroid-associated ophthalmopathy (TAO).
Ernst Nyström, Gertrud E. B. Berg, Svante K. G. Jansson, Ove Tørring, Stig V. Valdemarsson   +4 more
openaire   +1 more source